NASDAQ: AQST | Healthcare / Biotechnology / USA |
1.39 | +0.2200 | +18.80% | Vol 1.39M | 1Y Perf -67.95% |
Aug 11th, 2022 16:00 DELAYED |
BID | 1.30 | ASK | 1.42 | ||
Open | 1.17 | Previous Close | 1.17 | ||
Pre-Market | - | After-Market | 1.38 | ||
- - | -0.01 -0.72% |
Target Price | 6.50 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 367.63 | Finscreener Ranking | ★★★★+ 55.28 | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★+ 43.58 | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★ 47.28 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 13.35 | Earnings Rating | Strong Buy | |
Market Cap | 74.16M | Earnings Date | 2nd Aug 2022 | |
Alpha | -0.05 | Standard Deviation | 0.32 | |
Beta | 3.43 |
Today's Price Range 1.151.47 | 52W Range 0.61806.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 57.95% | ||
1 Month | 74.62% | ||
3 Months | 29.91% | ||
6 Months | -45.06% | ||
1 Year | -67.95% | ||
3 Years | -65.16% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 79.92 | |||
ROE last 12 Months | 95.33 | |||
ROA (5Y Avg) | -65.03 | |||
ROA last 12 Months | -116.65 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -107.70 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -107.70 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.50 | ||||
14.15 | ||||
1.11 | ||||
38.20 | ||||
-1.30 | ||||
-0.84 | ||||
-0.46 | ||||
-1.90 | ||||
84.87M | ||||
Forward PE | -1.18 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.40 | ||||
1.80 | ||||
- | ||||
- | ||||
-2.50 | ||||
Leverage Ratio | -0.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
68.40 | ||||
-94.80 | ||||
-89.20 | ||||
-122.70 | ||||
-91.51 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
36.64M | ||||
0.75 | ||||
-3.11 | ||||
-6.32 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.41 | -0.36 | 12.20 |
Q01 2022 | -0.45 | -0.32 | 28.89 |
Q04 2021 | -0.37 | -0.38 | -2.70 |
Q03 2021 | -0.40 | -0.37 | 7.50 |
Q02 2021 | -0.42 | -0.33 | 21.43 |
Q01 2021 | -0.44 | -0.41 | 6.82 |
Q04 2020 | -0.46 | -0.60 | -30.43 |
Q03 2020 | -0.50 | -0.49 | 2.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.41 | 8.89 | Positive |
9/2022 QR | -0.36 | 12.20 | Positive |
12/2022 FY | -1.34 | 18.29 | Positive |
12/2023 FY | -0.74 | -8.82 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -0.41 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.39M |
Shares Outstanding | 53.35K |
Shares Float | 37.06M |
Trades Count | 3.12K |
Dollar Volume | 1.82M |
Avg. Volume | 1.18M |
Avg. Weekly Volume | 2.01M |
Avg. Monthly Volume | 774.25K |
Avg. Quarterly Volume | 758.22K |
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 1.39 per share at the end of the most recent trading day (a 18.8% change compared to the prior day closing price) with a volume of 1.39M shares and market capitalization of 74.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.
The one-year performance of Aquestive Therapeutics Inc. stock is -67.95%, while year-to-date (YTD) performance is -64.27%. AQST stock has a five-year performance of %. Its 52-week range is between 0.618 and 6.4, which gives AQST stock a 52-week price range ratio of 13.35%
Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.11, a price to cashflow ratio of 38.20, a PEG ratio of 2.32, a ROA of -116.65%, a ROC of -107.70% and a ROE of 95.33%. The company’s profit margin is -91.51%, its EBITDA margin is -89.20%, and its revenue ttm is $36.64 Million , which makes it $0.75 revenue per share.
Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.5, which is +367.63% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aquestive Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.26, ATR14 : 0.14, CCI20 : 289.14, Chaikin Money Flow : -0.19, MACD : 0.07, Money Flow Index : 89.67, ROC : 72.67, RSI : 64.10, STOCH (14,3) : 88.06, STOCH RSI : 1.00, UO : 51.86, Williams %R : -11.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were: A. Mark Schobel (Buy at a value of $44 036), Daniel Barber (Buy at a value of $88 073), Lori J. Braender (Buy at a value of $13 211), Peter Boyd (Buy at a value of $6 251)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.
CEO: Keith J. Kendall
Telephone: +1 908 941-1900
Address: 30 Technology Drive, Warren 07059, NJ, US
Number of employees: 232
Thu, 16 Jun 2022 15:35 GMT Aquestive Therapeutics (AQST) Received its Third Buy in a Row
- TipRanks. All rights reserved.Wed, 18 May 2022 04:45 GMT Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Logicbio Therapeutics (LOGC)
- TipRanks. All rights reserved.Wed, 04 May 2022 17:25 GMT Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities
- TipRanks. All rights reserved.Wed, 04 May 2022 16:37 GMT Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush
- TipRanks. All rights reserved.Wed, 09 Mar 2022 21:05 GMT Aquestive Therapeutics (AQST) Gets a Buy Rating from JMP Securities
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.